États-Unis · Agences & temps réel · PR Newswire

Lumen Bio Reports Positive Phase 2 Results from the RePreve Clinical Trial (LMN-201 for C. difficile Infection)

Publié par PR Newswire · États-Unis il y a 1 h

- Global cure observed in 83.3% of LMN-201 recipients versus 36.4% randomized to placebo - LMN-201 treatment plus standard-of-care antibiotics demonstrated a six-fold reduction in…

Lire l'article complet sur PR Newswire Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.prnewswire.com)

Lumen Bio Reports Positive Phase 2 Results from the RePreve Clinical Trial (LMN-201 for C. difficile Infection)

À lire aussi

Here’s why Rubio is visiting a small Indian city home to world’s largest oil-refining complex

Accenture, Dragos and SANS Institute Launch Foundation to Strengthen Cyber Defenses for Under-Resourced U.S. Utilities

Episode 49: Trump’s Tariffs Give Forced-Labor Activists an Opening

MT Newswires' MCP Server Now Available in Perplexity Computer, Bringing Real-Time Global Market News to AI-Driven Workflows

Lumen Bio Reports Positive Phase 2 Results from the RePreve Clinical Trial (LMN-201 for C. difficile Infection)

Partager

À lire aussi

Here’s why Rubio is visiting a small Indian city home to world’s largest oil-refining complex

Accenture, Dragos and SANS Institute Launch Foundation to Strengthen Cyber Defenses for Under-Resourced U.S. Utilities

Episode 49: Trump’s Tariffs Give Forced-Labor Activists an Opening

MT Newswires' MCP Server Now Available in Perplexity Computer, Bringing Real-Time Global Market News to AI-Driven Workflows